Home
Clinical Trials
Catheter Ablation for Functio...

Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation: Development and Validation of a Predictive Model-A Multicenter Prospective Cohort Study

Last Updated: 2025-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

556 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-31

Study Completion Date

2027-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mitral Regurgitation (MR) is the most prevalent type of valvular heart disease in clinical practice, with an average prevalence of approximately 1% in populations with moderate-to-severe or worse MR, which increases significantly with age. Functional MR (FMR) is one subtype of MR and can be further classified into atrial FMR, ventricular FMR, and mixed FMR based on its underlying mechanisms. Pathophysiologically, FMR is closely associated with atrial fibrillation (AF) and heart failure (HF). Studies suggest that catheter ablation for AF may improve FMR in some patients and reverse left atrial (LA) and left ventricular (LV) remodeling. However, there is currently a lack of precise and effective indicators or predictive models to determine the evolution of FMR after AF ablation in both domestic and international research.

This study aims to conduct a multicenter prospective cohort study, enrolling patients with moderate or worse FMR and persistent AF undergoing ablation. Using postoperative 3-month FMR improvement as the primary outcome, we will employ big data mining and multimodal analysis to construct a predictive model for FMR progression after AF ablation and validate it through prospective multicenter testing. The findings will provide a scientific basis for clinical decision-making and precision medicine in this patient population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Atrial Fibrillation Combined with Atrial Functional Mitral Regurgitation

NCT06630936

Atrial Fibrillation (AF) Atrial Functional Mitral Regurgitation

RECRUITING

Bi-atrial Versus Left Atrial Ablation for Patients With Rheumatic Mitral Valve Disease and Non-paroxysmal Atrial Fibrillation

NCT05021601

Persistent Atrial Fibrillation

RECRUITING NA

Catheter Ablation and Rate Control of Atrial Fibrillation in Patients With Heart Failure

NCT02846922

Catheter Ablation Rate Control Heart Failure +1 more

COMPLETED

EARLY-MYO-AF Registry

NCT04512222

Atrial Fibrillation Atrial Flutter

RECRUITING

Termination of Persistent Atrial Fibrillation by Catheter Ablation

NCT04958928

Atrial Fibrillation

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AF Ablation Patients With Moderate+ FMR and Persistent AF

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation

Catheter Ablation

Intervention Type PROCEDURE

A minimally invasive procedure that delivers energy through catheters to destroy abnormal cardiac tissue causing arrhythmias.

ultrasonic cardiography (UCG)

Intervention Type DIAGNOSTIC_TEST

Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surfa

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Catheter Ablation

A minimally invasive procedure that delivers energy through catheters to destroy abnormal cardiac tissue causing arrhythmias.

Intervention Type PROCEDURE

ultrasonic cardiography (UCG)

Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surfa

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged 18-75 years
2. Diagnosis of functional mitral regurgitation (FMR) by transthoracic echocardiography (TTE) and/or transesophageal echocardiography (TEE) with combined qualitative and quantitative assessment, demonstrating moderate or worse regurgitation (≥ grade 2+)
3. Persistent atrial fibrillation (AF) with successful catheter ablation
4. Signed informed consent with commitment to regular follow-up for ≥1 year

Exclusion Criteria

1. Acute or chronic degenerative mitral regurgitation (DMR) from any etiology
2. Paroxysmal or permanent atrial fibrillation
3. Planned repeat ablation for AF recurrence
4. Concomitant moderate/severe valvular disease (e.g., mitral stenosis, aortic stenosis/regurgitation, pulmonary stenosis/regurgitation)
5. Prior valvular surgery/intervention
6. History of open-heart surgery
7. Severe pulmonary hypertension (PASP \>70 mmHg) refractory to medical therapy
8. Left atrial diameter ≥60 mm (diastolic phase) on echocardiography
9. Uncontrolled hyperthyroidism
10. Intracardiac mass/thrombus/vegetation
11. Significant shunts (ASD/VSD/PDA)
12. Hypertrophic obstructive cardiomyopathy
13. Active severe infection/sepsis (including infective endocarditis)
14. Scheduled CRT/CRT-D/CCM implantation
15. Untreated critical CAD (e.g., ≥70% stenosis in proximal/mid LAD/LCX/RCA requiring revascularization) or concomitant major cardiovascular surgery needs
16. End-stage heart failure (ACC/AHA Stage D) requiring mechanical support/transplant listing
17. Severe hepatic dysfunction (acute liver failure/decompensated cirrhosis, Child-Pugh C)
18. Severe renal impairment (CKD 5: eGFR\<15 mL/min or dialysis)
19. Hemodynamic instability (SBP\<90 mmHg/MAP\<70 mmHg with hypoperfusion \[urine output\<30 mL/h\])
20. Contraindications to antithrombotics: Active bleeding (GI/intracranial/visceral), bleeding disorders (hemophilia/ITP/leukemia etc.), severe hematologic abnormalities (platelets\<20×10⁹/L, spontaneous INR\>3)
21. Uncontrolled autoimmune/connective tissue disease
22. Acute MI within 4 weeks
23. Stroke within 30 days
24. Acute peptic ulcer/upper GI bleeding within 3 months
25. Pregnancy/lactation
26. Declined informed consent
27. Life expectancy \<1 year
28. Poor compliance (anticipated inability to complete follow-up)
29. Concurrent participation in conflicting clinical trials
30. Other investigator-determined exclusions.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers